In vitro cellular assays have demonstrated that the PARP inhibitor olaparib activates the cGAS/STING pathway in triple-negative breast cancer cells, and in vivo experiments have further revealed that olaparib also induces the activation of the STING/TBK1/IRF3 pathway, which assists DCs in recognizing tumor antigens and further recruits and activates CD8+ T cells. The gene discussed is PARP1; the disease is neoplasm.